Panobinostat

Summary

Panobinostat (CHEMBL483254) is an approved small-molecule EC 3.5.1.98 (histone deacetylase) inhibitor (ATC L01XH03) targeting HDAC2, HDAC3, and HDAC6; indicated across 52 conditions including neoplasm and plasma cell myeloma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01XH03
• Targets: 8 (HDAC2, HDAC3, HDAC6…)
• Indications: 52 conditions
• Clinical trials: 139
• Chemistry: 349.4 Da · C21H23N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL483254
Name	Panobinostat
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6918837
ChEBI	CHEBI:85990
ATC	L01XH03
Molecular formula	C21H23N3O2
Molecular weight	349.4
InChIKey	FPOHNWQLNRZRFC-ZHACJKMWSA-N

SMILES: CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO

IUPAC name: (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide

ChEBI definition: A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.

Pharmacological roles (ChEBI): EC 3.5.1.98 (histone deacetylase) inhibitor, antineoplastic agent, angiogenesis modulating agent.

Also known as: Farydak, LBH-589, LBH589, Panobinostat, Panobinostat hydrate, PANOBINOSTAT, Panobinostat lactateÊ, Panobinostat lactateÂ, C0088743, Panobinostat; Farydak

Parent form; salt/anhydrous children: CHEMBL3545368

Patent coverage: 4,546 distinct patent families (11,666 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,841 (84%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HDAC2	histone deacetylase 2	Inhibition	8.52	3.1%	Q92769
HDAC3	histone deacetylase 3	Inhibition	8.4	95.1% (common-essential)	O15379
HDAC6	histone deacetylase 6	Inhibition	7.21	0%	Q9UBN7
HDAC8	histone deacetylase 8	Inhibition	6.61	4.9%	Q9BY41
HDAC9	histone deacetylase 9	Inhibition	8.52	0%	Q9UKV0
HDAC1	histone deacetylase 1	Inhibition	8.52	4.5%	Q13547
HDAC4	histone deacetylase 4	Inhibition	7.92	3.1%	P56524
HDAC7	histone deacetylase 7	Inhibition	7.85	4.2%	Q8WUI4
	Plasmodium falciparum histone deacetylase 1		6.03

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Phosphatidylinositol 3-kinase catalytic subunit type 3, Bromodomain-containing protein 4, Histone deacetylase 3, Protein deacetylase HDAC6, Histone deacetylase 2, Histone deacetylase, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2), Histone deacetylase 5, Histone deacetylase 7, Histone deacetylase 8.

Bioactivity

ChEMBL activities: 248 potent at pChembl ≥ 5 of 249 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HDAC3	10	Ki	0.1	nM	CHEMBL_ACT_25472505
HDAC1	9.3	IC50	0.5	nM	CHEMBL_ACT_23315943
HDAC1	9.27	Ki	0.54	nM	CHEMBL_ACT_18679416
HDAC1	9.22	IC50	0.6	nM	CHEMBL_ACT_19195782
HDAC4	9.22	Ki	0.6	nM	CHEMBL_ACT_6371556
HDAC2	9.19	Ki	0.65	nM	CHEMBL_ACT_3389965
HDAC2	9.15	Ki	0.7	nM	CHEMBL_ACT_15656398
HDAC5	9.15	Ki	0.7	nM	CHEMBL_ACT_6371570
HDAC6	9.15	Ki	0.7	nM	CHEMBL_ACT_6371584
HDAC3	9.12	IC50	0.75	nM	CHEMBL_ACT_28068464
HDAC3	9.08	IC50	0.83	nM	CHEMBL_ACT_16647301
HDAC1	9	Ki	1	nM	CHEMBL_ACT_15656409
HDAC1	9	IC50	1	nM	CHEMBL_ACT_16506957
HDAC1	9	IC50	1	nM	CHEMBL_ACT_16645633
HDAC4	9	IC50	1	nM	CHEMBL_ACT_26150519
HDAC6	9	IC50	1	nM	CHEMBL_ACT_26150524
HDAC1	9	Ki	1	nM	CHEMBL_ACT_3389964
HDAC3	8.96	Ki	1.1	nM	CHEMBL_ACT_15656388
HDAC3	8.96	Ki	1.1	nM	CHEMBL_ACT_3389966
HDAC9	8.92	Ki	1.2	nM	CHEMBL_ACT_6371626
HDAC1	8.9	IC50	1.26	nM	CHEMBL_ACT_16646168
HDAC1	8.85	IC50	1.4	nM	CHEMBL_ACT_18980580
HDAC6	8.82	Ki	1.5	nM	CHEMBL_ACT_15656465
HDAC3	8.82	IC50	1.5	nM	CHEMBL_ACT_18980586
HDAC6	8.82	Ki	1.5	nM	CHEMBL_ACT_3389969
HDAC11	8.8	IC50	1.6	nM	CHEMBL_ACT_18980600
HDAC1	8.79	IC50	1.61	nM	CHEMBL_ACT_28068458
HDAC3	8.78	IC50	1.67	nM	CHEMBL_ACT_19013992
HDAC1	8.75	IC50	1.78	nM	CHEMBL_ACT_19014000
HDAC6	8.75	IC50	1.77	nM	CHEMBL_ACT_28068497

Target pathways

Aggregated over 8 target gene(s): HDAC2, HDAC3, HDAC6, HDAC8, HDAC9, HDAC1, HDAC4, HDAC7.

Top Reactome pathways

71 total, by targets touching each:

Pathway	Targets	Genes
NOTCH1 Intracellular Domain Regulates Transcription	8	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 PEST Domain Mutants	8	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	8	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
Notch-HLH transcription pathway	8	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	8	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
HDACs deacetylate histones	4	HDAC1, HDAC2, HDAC3, HDAC8
Regulation of PTEN gene transcription	4	HDAC1, HDAC2, HDAC3, HDAC7
p75NTR negatively regulates cell cycle via SC1	3	HDAC1, HDAC2, HDAC3
SUMOylation of chromatin organization proteins	3	HDAC1, HDAC2, HDAC4
Regulation of MECP2 expression and activity	3	HDAC1, HDAC2, HDAC3
STAT3 nuclear events downstream of ALK signaling	3	HDAC1, HDAC2, HDAC3
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression	2	HDAC1, HDAC2
NoRC negatively regulates rRNA expression	2	HDAC1, HDAC2
Regulation of TP53 Activity through Acetylation	2	HDAC1, HDAC2
RNA Polymerase I Transcription Initiation	2	HDAC1, HDAC2
RUNX2 regulates osteoblast differentiation	2	HDAC3, HDAC6
MECP2 regulates neuronal receptors and channels	2	HDAC1, HDAC2
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	2	HDAC1, HDAC2
Potential therapeutics for SARS	2	HDAC1, HDAC2
Negative Regulation of CDH1 Gene Transcription	2	HDAC1, HDAC2
Factors involved in megakaryocyte development and platelet production	2	HDAC1, HDAC2
Regulation of endogenous retroelements by KRAB-ZFP proteins	2	HDAC1, HDAC2
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	2	HDAC1, HDAC2
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	2	HDAC1, HDAC2
NuRD complex assembly	2	HDAC1, HDAC2
Interaction of NuRD complexes with transcription factors	2	HDAC1, HDAC2
Transcription of E2F targets under negative control by DREAM complex	1	HDAC1
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	1	HDAC1
G0 and Early G1	1	HDAC1
PPARA activates gene expression	1	HDAC3

Dominant GO biological processes

GO term	Targets
chromatin organization	8
negative regulation of transcription by RNA polymerase II	7
negative regulation of DNA-templated transcription	7
protein deacetylation	5
positive regulation of transcription by RNA polymerase II	4
epigenetic regulation of gene expression	4
negative regulation of gene expression, epigenetic	4
chromatin remodeling	3
positive regulation of cell population proliferation	3
heterochromatin formation	3
circadian regulation of gene expression	3
positive regulation of intracellular estrogen receptor signaling pathway	3
negative regulation of apoptotic process	3
positive regulation of DNA-templated transcription	3
rhythmic process	3

Indications & clinical

Indications

52 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
Hodgkins lymphoma	3	MONDO:0004952	EFO:0000183
primary cutaneous T-cell non-Hodgkin lymphoma	2	MONDO:0000607	EFO:0002913
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
chronic myeloid leukemia	2	MONDO:0011996	EFO:0000339
glioblastoma	2	MONDO:0018177	EFO:0000519
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
thyroid gland carcinoma	2	MONDO:0015075	EFO:0002892
non-Hodgkin lymphoma	2	MONDO:0018908	EFO:0005952
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
leukemia	2	MONDO:0005059	EFO:0000565
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
acute lymphoblastic leukemia	2	MONDO:0004967	EFO:0000220
clear cell renal carcinoma	2	MONDO:0005005	EFO:0000349
lymphoma	2	MONDO:0005062	EFO:0000574
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
plasma cell leukemia	2	MONDO:0018689	EFO:0006475
plasmacytoma	2	MONDO:0005615	EFO:0006738
Waldenstrom macroglobulinemia	2	MONDO:0100280	EFO:0009441
diffuse intrinsic pontine glioma	2	MONDO:0006033	EFO:1000026
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
breast neoplasm	2	MONDO:0021100	MONDO:0007254
graft versus host disease	2	MONDO:0013730	MONDO:0013730
hematopoietic and lymphoid system neoplasm	2	MONDO:0002334	MONDO:0044881
glioma	2	MONDO:0021042	MONDO:0100342
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
melanoma	1	MONDO:0005105	EFO:0000756
HIV infectious disease	1	MONDO:0005109	EFO:0000764
hepatocellular carcinoma	1	MONDO:0007256	EFO:0000182
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673
acquired polycythemia vera	1	MONDO:0009891	EFO:0002429
primary myelofibrosis	1	MONDO:0009692	EFO:0002430
metastatic melanoma	1	MONDO:0005191	EFO:0002617
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
nasopharyngeal neoplasm	1	MONDO:0005375	EFO:0004252
mantle cell lymphoma	1	MONDO:0018876	EFO:1001469
chronic myelomonocytic leukemia	1	MONDO:0020311	EFO:1001779
rectal cancer	1	MONDO:0006519	EFO:1000657
lung neoplasm	1	MONDO:0021117	MONDO:0008903
colonic neoplasm	1	MONDO:0005401	MONDO:0021063
skin neoplasm	1	MONDO:0002531	MONDO:0002898
sickle cell disease	1	MONDO:0011382	MONDO:0011382
plasma cell neoplasm	1	MONDO:0004959	EFO:0000200
paraganglioma	1	MONDO:0000448	EFO:1000453

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 139.

Phase distribution

Phase	Trials
PHASE1	57
PHASE2	49
PHASE1/PHASE2	25
PHASE3	3
Not specified	3
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02386800	PHASE4	ACTIVE_NOT_RECRUITING	CINC424A2X01B Rollover Protocol
NCT01023308	PHASE3	COMPLETED	Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
NCT01034163	PHASE3	COMPLETED	A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin’s Lymphoma (HL)
NCT04326764	PHASE3	TERMINATED	Panobinostat Maintenance After HSCT fo High-risk AML and MDS
NCT05725200	PHASE2	RECRUITING	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
NCT00425555	PHASE2	COMPLETED	Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00445068	PHASE2	TERMINATED	Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
NCT00449761	PHASE2	TERMINATED	Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
NCT00451035	PHASE2	TERMINATED	Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase
NCT00490776	PHASE2	TERMINATED	Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
NCT00550277	PHASE2	COMPLETED	LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
NCT00567879	PHASE1/PHASE2	TERMINATED	A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
NCT00594230	PHASE2	TERMINATED	LBH589 in Refractory Myelodysplastic Syndromes (MDS)
NCT00621244	PHASE1/PHASE2	COMPLETED	A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
NCT00667862	PHASE2	COMPLETED	Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
NCT00690677	PHASE2	COMPLETED	Phase II Trial of LBH589 in Refractory Colorectal Cancer
NCT00691938	PHASE1/PHASE2	COMPLETED	LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
NCT00699296	PHASE2	TERMINATED	Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
NCT00723203	PHASE2	TERMINATED	Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT00742027	PHASE2	COMPLETED	Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin’s Lymphoma
NCT00743288	PHASE1/PHASE2	COMPLETED	Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
NCT00777049	PHASE2	COMPLETED	Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
NCT00840346	PHASE1/PHASE2	COMPLETED	Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
NCT00848523	PHASE2	TERMINATED	Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
NCT00859222	PHASE1/PHASE2	COMPLETED	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
NCT00878436	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
NCT00880269	PHASE2	COMPLETED	Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
NCT00901147	PHASE2	COMPLETED	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
NCT00918333	PHASE1/PHASE2	COMPLETED	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
NCT00925132	PHASE1/PHASE2	TERMINATED	Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
NCT00931762	PHASE2	TERMINATED	A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
NCT00936611	PHASE2	COMPLETED	LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s Macroglobulinemia
NCT00939159	PHASE2	TERMINATED	Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT00946647	PHASE1/PHASE2	COMPLETED	A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
NCT00967044	PHASE1/PHASE2	COMPLETED	Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
NCT00978432	PHASE2	TERMINATED	Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00985946	PHASE2	TERMINATED	Study of Panobinostat in Patients With Neuroendocrine Tumors
NCT01013597	PHASE2	COMPLETED	Trial of LBH589 in Metastatic Thyroid Cancer
NCT01028313	PHASE2	WITHDRAWN	A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
NCT01034657	PHASE2	TERMINATED	LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

96 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
BELINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
CELECOXIB	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
GIVINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
PHENYLBUTANOIC ACID	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
ROMIDEPSIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
SODIUM PHENYLBUTYRATE	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
VORINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
ABEXINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
CAFFEIC ACID	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
CURCUMIN	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
ENTINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
PRACINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
TACEDINALINE	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
TUCIDINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
AR-42	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
CHLOROGENIC ACID	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
DACINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
FIMEPINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
NANATINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
QUISINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
Pazopanib	PubChem	Approved	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
RICOLINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8
BENDAMUSTINE	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC8
CITARINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC6, HDAC7, HDAC8
TINOSTAMUSTINE	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC8
BORTEZOMIB	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
MOCETINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
BUTYRIC ACID	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC8
DOMATINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC9
SODIUM BUTYRATE	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC8
ATORVASTATIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC6
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC6, HDAC8
LOVASTATIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC6
EBSELEN	ChEMBL	Phase 3	HDAC2, HDAC6, HDAC9
BAICALEIN	ChEMBL	Phase 2	HDAC1, HDAC6, HDAC8
Crizotinib	PubChem	Approved	HDAC1, HDAC2, HDAC6
VALPROIC ACID	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2
MOLIBRESIB	ChEMBL	Phase 2	HDAC1, HDAC2
NICOXAMAT	ChEMBL	Phase 2	HDAC1, HDAC6
RESMINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC6
.gamma.-aminobutyric acid	PubChem	Approved	HDAC7, HDAC9
acetylcysteine	PubChem	Approved	HDAC7, HDAC9
Idelalisib	PubChem	Approved	HDAC1, HDAC6
ABAMETAPIR	ChEMBL	Phase 4 (approved)	HDAC6
ATALUREN	ChEMBL	Phase 4 (approved)	HDAC6
AXITINIB	ChEMBL	Phase 4 (approved)	HDAC6
BUFEXAMAC	ChEMBL	Phase 4 (approved)	HDAC6
EVANS BLUE FREE ACID	ChEMBL	Phase 4 (approved)	HDAC6
EXIFONE	ChEMBL	Phase 4 (approved)	HDAC1
FEBUXOSTAT	ChEMBL	Phase 4 (approved)	HDAC6
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HDAC6
GENTIAN VIOLET	ChEMBL	Phase 4 (approved)	HDAC6
INDOPROFEN	ChEMBL	Phase 4 (approved)	HDAC6
MARIBAVIR	ChEMBL	Phase 4 (approved)	HDAC6
MOMELOTINIB	ChEMBL	Phase 4 (approved)	HDAC1
MONOBENZONE	ChEMBL	Phase 4 (approved)	HDAC6
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	HDAC6
PHENYL AMINOSALICYLATE	ChEMBL	Phase 4 (approved)	HDAC6
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	HDAC6
RUXOLITINIB	ChEMBL	Phase 4 (approved)	HDAC6